{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:16:41Z","timestamp":1788139001505,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemical pleurodesis is a standard palliative intervention for recurrent malignant pleural effusion (MPE). Historically, patient rotation after sclerosant instillation was routine to ensure uniform drug distribution, but evidence supporting this practice remains conflicting. The study question was, does doxycycline pleurodesis without patient rotation demonstrate comparable efficacy and safety to the standard rotation protocol?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This pilot randomized trial included 40 patients with recurrent MPE eligible for pleurodesis. Patients were randomized (1:1) to either a Rotation group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), which underwent a 2-h sequential rotation, or a Non-Rotation group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), which remained supine. The primary outcome was pleurodesis success at 1\u00a0month, assessed by chest ultrasonography. The secondary outcome was the Pleural Adherence Score (PAS) to objectively assess drug distribution and pain assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age was 56.5\u00a0years. Pleurodesis success rates were identical between the rotation and non-rotation groups 85% (17\/20) vs. 85% (17\/20);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.99, though the confidence interval was wide (\u2212\u200922.13% to 22.13%). Crucially, ultrasound-derived PAS scores at day 1 were high and comparable between groups (Mean 20.0 vs. 21.2;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.33), confirming effective sclerosant distribution without rotation. There were no significant differences in pain scores, drainage duration, or complication rates between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Omitting patient rotation during doxycycline pleurodesis for MPE demonstrated comparable 1-month efficacy in this pilot study, though larger trials are needed to establish definitive equivalence. These findings support a simplified non-rotation protocol to reduce patient burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial was retrospectively registered at ClinicalTrials.gov (Identifier: NCT07147270). ClinicalTrials.gov PRS: Home page (Modernized) published 08\/29\/2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04630-3","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:14:21Z","timestamp":1788135261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of patient positioning on the efficacy and safety of doxycycline pleurodesis in malignant pleural effusion: a pilot randomized trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0872-7103","authenticated-orcid":false,"given":"Hieba Gamal","family":"Ezzelregal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Mohamed","family":"Abdelsamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"1","key":"4630_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/OP.23.00387","volume":"20","author":"M Munavvar","year":"2024","unstructured":"Munavvar M, Khan MA, Roberts ME. Current trends in treating malignant pleural effusion: evidence, guidelines, and best practice recommendations. JCO Oncol Pract. 2024;20(1):15\u201324. https:\/\/doi.org\/10.1200\/OP.23.00387.","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"4630_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2015.12.001","volume":"149","author":"JM Porcel","year":"2016","unstructured":"Porcel JM. Quality of life in patients with malignant pleural effusions. Chest. 2016;149(3):888\u201395. https:\/\/doi.org\/10.1016\/j.chest.2015.12.001.","journal-title":"Chest"},{"issue":"suppl 3","key":"4630_CR3","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/thorax-2022-219784","volume":"78","author":"ME Roberts","year":"2023","unstructured":"Roberts ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP, et al. British Thoracic Society guideline for pleural disease. Thorax. 2023;78(suppl 3):s1\u201342. https:\/\/doi.org\/10.1136\/thorax-2022-219784.","journal-title":"Thorax"},{"issue":"6","key":"4630_CR4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1378\/chest.105.6.1743","volume":"105","author":"JE Heffner","year":"1994","unstructured":"Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest. 1994;105(6):1743\u20137. https:\/\/doi.org\/10.1378\/chest.105.6.1743.","journal-title":"Chest"},{"issue":"6","key":"4630_CR5","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1378\/chest.104.6.1763","volume":"104","author":"SR Dryzer","year":"1993","unstructured":"Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest. 1993;104(6):1763\u20136. https:\/\/doi.org\/10.1378\/chest.104.6.1763.","journal-title":"Chest"},{"issue":"1","key":"4630_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0169-5002(01)00475-5","volume":"36","author":"HJ Mager","year":"2002","unstructured":"Mager HJ, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer. 2002;36(1):77\u201381. https:\/\/doi.org\/10.1016\/S0169-5002(01)00475-5.","journal-title":"Lung Cancer"},{"issue":"3","key":"4630_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1378\/chest.93.3.527","volume":"93","author":"DG Lorch","year":"1988","unstructured":"Lorch DG, Gordon L, Wooten S, Strange C, Sahn SA. Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest. 1988;93(3):527\u20139. https:\/\/doi.org\/10.1378\/chest.93.3.527.","journal-title":"Chest"},{"issue":"15","key":"4630_CR8","first-page":"2806","volume":"126","author":"AK Janmeja","year":"2013","unstructured":"Janmeja AK, Mohapatra PR, Shrestha P. Rotation versus non-rotation of the patient for thoracoscopic talc poudrage pleurodesis. Chin Med J (Engl). 2013;126(15):2806\u201310.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"4630_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43168-020-00009-y","volume":"14","author":"KM Magdy","year":"2020","unstructured":"Magdy KM, Hieba EG. Outcome of ultrasound-guided, single-session pleurodesis in malignant pleural effusion. Egypt J Bronchol. 2020;14(1):1\u20137. https:\/\/doi.org\/10.1186\/s43168-020-00009-y.","journal-title":"Egypt J Bronchol"},{"issue":"5","key":"4630_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chest.2018.08.1031","volume":"154","author":"JP Corcoran","year":"2018","unstructured":"Corcoran JP, Hallifax RJ, Mercer RM, Yousuf A, Asciak R, Hassan M. Thoracic ultrasound as an early predictor of pleurodesis success in malignant pleural effusion. Chest. 2018;154(5):1115\u201320. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1031.","journal-title":"Chest"},{"issue":"3","key":"4630_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/resp.13937","volume":"26","author":"U Chaddha","year":"2021","unstructured":"Chaddha U, Agrawal A, Bhavani SV, Sivertsen K, Donington DJ, Ferguson MK. Thoracic ultrasound as a predictor of pleurodesis success at the time of indwelling pleural catheter removal. Respirology. 2021;26(3):249\u201354. https:\/\/doi.org\/10.1111\/resp.13937.","journal-title":"Respirology"},{"key":"4630_CR12","doi-asserted-by":"publisher","unstructured":"Ekpe EE, Etiuma AU, Akpan AF. Does intraprocedure patient positioning affect outcome of chemical pleurodesis for malignant pleural effusion? Ibom Med J. 2024;17(3):534\u2013539. https:\/\/doi.org\/10.61386\/imj.v17i3.515","DOI":"10.61386\/imj.v17i3.515"},{"issue":"5","key":"4630_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/0003-4975(93)90017-C","volume":"55","author":"LA Robinson","year":"1993","unstructured":"Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg. 1993;55(5):1115\u201321. https:\/\/doi.org\/10.1016\/0003-4975(93)90017-C.","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"4630_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","volume":"198","author":"DJ Feller-Kopman","year":"2018","unstructured":"Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T. Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198(7):839\u201349. https:\/\/doi.org\/10.1164\/rccm.201807-1415ST.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04630-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:08:35Z","timestamp":1788138515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04630-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4630"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04630-3","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the local Institutional Ethics Committee. Written informed consent was obtained from all participants before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no financial or non-financial conflicts of interest related to the subject matter or materials discussed in this manuscript. No pharmaceutical industry supports or involvement were utilized in the design, conduct, or reporting of this study.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"384"}}